These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 34415800)

  • 1. Characteristics of SARS-CoV2 that may be useful for nanoparticle pulmonary drug delivery.
    Rabiei M; Kashanian S; Samavati SS; Derakhshankhah H; Jamasb S; McInnes SJP
    J Drug Target; 2022 Mar; 30(3):233-243. PubMed ID: 34415800
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nanoparticle-mediated pulmonary drug delivery: a review.
    Paranjpe M; Müller-Goymann CC
    Int J Mol Sci; 2014 Apr; 15(4):5852-73. PubMed ID: 24717409
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Specific delivering of RNAi using Spike's aptamer-functionalized lipid nanoparticles for targeting SARS-CoV-2: A strong anti-Covid drug in a clinical case study.
    Saify Nabiabad H; Amini M; Demirdas S
    Chem Biol Drug Des; 2022 Feb; 99(2):233-246. PubMed ID: 34714580
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A nanotechnological approach in the current therapy of COVID-19: model drug oseltamivir-phosphate loaded PLGA nanoparticles targeted with spike protein binder peptide of SARS-CoV-2.
    Ucar B; Acar T; Arayici PP; Derman S
    Nanotechnology; 2021 Sep; 32(48):. PubMed ID: 34375967
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development and evaluation of inhalable composite niclosamide-lysozyme particles: A broad-spectrum, patient-adaptable treatment for coronavirus infections and sequalae.
    Brunaugh AD; Seo H; Warnken Z; Ding L; Seo SH; Smyth HDC
    PLoS One; 2021; 16(2):e0246803. PubMed ID: 33571320
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Silver nanoparticle-based drug delivery systems in the fight against COVID-19: enhancing efficacy, reducing toxicity and improving drug bioavailability.
    Yoosefian M; Sabaghian H
    J Drug Target; 2024 Aug; 32(7):794-806. PubMed ID: 38742854
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nanomedicines via the pulmonary route: a promising strategy to reach the target?
    Guérin M; Lepeltier E
    Drug Deliv Transl Res; 2024 Aug; 14(8):2276-2297. PubMed ID: 38587757
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ivermectin: an award-winning drug with expected antiviral activity against COVID-19.
    Formiga FR; Leblanc R; de Souza Rebouças J; Farias LP; de Oliveira RN; Pena L
    J Control Release; 2021 Jan; 329():758-761. PubMed ID: 33038449
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Optimizing use of theranostic nanoparticles as a life-saving strategy for treating COVID-19 patients.
    Itani R; Tobaiqy M; Al Faraj A
    Theranostics; 2020; 10(13):5932-5942. PubMed ID: 32483428
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pulmonary drug delivery: a role for polymeric nanoparticles?
    d'Angelo I; Conte C; Miro A; Quaglia F; Ungaro F
    Curr Top Med Chem; 2015; 15(4):386-400. PubMed ID: 25579350
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gallium Components-Based Drug Delivery: A Potential Treatment for COVID-19.
    Torabi S; Bahreini F; Rezaei N
    Infect Disord Drug Targets; 2022; 22(3):e270122200590. PubMed ID: 35086461
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nitric oxide (NO) and nanoparticles - Potential small tools for the war against COVID-19 and other human coronavirus infections.
    Pieretti JC; Rubilar O; Weller RB; Tortella GR; Seabra AB
    Virus Res; 2021 Jan; 291():198202. PubMed ID: 33086123
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Red blood cell-hitchhiking mediated pulmonary delivery of ivermectin: Effects of nanoparticle properties.
    Zheng J; Lu C; Ding Y; Zhang J; Tan F; Liu J; Yang G; Wang Y; Li Z; Yang M; Yang Y; Gong W; Gao C
    Int J Pharm; 2022 May; 619():121719. PubMed ID: 35390488
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nanomedicine in pulmonary delivery.
    Mansour HM; Rhee YS; Wu X
    Int J Nanomedicine; 2009; 4():299-319. PubMed ID: 20054434
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pulmonary drug delivery devices and nanosystems as potential treatment strategies for acute respiratory distress syndrome (ARDS).
    Dhege CT; Kumar P; Choonara YE
    Int J Pharm; 2024 May; 657():124182. PubMed ID: 38697584
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Testing the efficacy and safety of BIO101, for the prevention of respiratory deterioration, in patients with COVID-19 pneumonia (COVA study): a structured summary of a study protocol for a randomised controlled trial.
    Dioh W; Chabane M; Tourette C; Azbekyan A; Morelot-Panzini C; Hajjar LA; Lins M; Nair GB; Whitehouse T; Mariani J; Latil M; Camelo S; Lafont R; Dilda PJ; Veillet S; Agus S
    Trials; 2021 Jan; 22(1):42. PubMed ID: 33430924
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Repurposing of chlorpromazine in COVID-19 treatment: the reCoVery study].
    Plaze M; Attali D; Petit AC; Blatzer M; Simon-Loriere E; Vinckier F; Cachia A; Chrétien F; Gaillard R
    Encephale; 2020 Jun; 46(3S):S35-S39. PubMed ID: 32387014
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhaled interferons beta and SARS-COV2 infection: a preliminary therapeutic perspective.
    Cojocaru E; Cojocaru C; Antoniu SA; Stafie CS; Rajnoveanu A; Rajnoveanu RM
    Expert Rev Respir Med; 2022 Mar; 16(3):257-261. PubMed ID: 34793285
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Drug repurposing approach to combating coronavirus: Potential drugs and drug targets.
    Xu J; Xue Y; Zhou R; Shi PY; Li H; Zhou J
    Med Res Rev; 2021 May; 41(3):1375-1426. PubMed ID: 33277927
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Peritoneal Administration of a Subunit Vaccine Encapsulated in a Nanodelivery System Not Only Augments Systemic Responses against SARS-CoV-2 but Also Stimulates Responses in the Respiratory Tract.
    Jearanaiwitayakul T; Apichirapokey S; Chawengkirttikul R; Limthongkul J; Seesen M; Jakaew P; Trisiriwanich S; Sapsutthipas S; Sunintaboon P; Ubol S
    Viruses; 2021 Nov; 13(11):. PubMed ID: 34835008
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.